Currently, 175 patients with CKD are enrolled in the Phase 2/3 study (NCT03303066), which aims to assess the efficacy (percentage of people with an Hb increase that allows life without transfusion) and the safety of roxadustat in a lower risk of MDS. Here, GSTM1 is linked to myelodysplastic syndrome.